Has Atif Shaikh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $958 in general payments to Atif Shaikh, MD across 45 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Atif Shaikh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Atif Shaikh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Atif Shaikh, MD

Cardiovascular Disease · West Reading, PANPI 1144568312

Payments from drug & device makers

$958in general payments, 2019–2025

Across 45 payments — averaging $21.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$468
E.r. Squibb & Sons, L.L.C.$263
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$73
Johnson & Johnson$57
Medtronic$40
AbbVie$25
plus $32 from 2 others

What the payments were for

Food & beverage$958100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	23	$468
E.r. Squibb & Sons, L.L.C.	13	$263
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	3	$73
Johnson & Johnson	2	$57
Medtronic	1	$40
AbbVie	1	$25
Novartis	1	$17
AstraZeneca	1	$15

How this compares

$958 in reported general payments places this provider in the 35th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$154,085

Medicare patients

1,430

Services billed

2,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	96	$104,584
Repatha SureclickEvolocumab	21	$26,215
XareltoRivaroxaban	13	$16,695
JardianceEmpagliflozin	12	$6,897
Metoprolol Succinate	235	$3,825
Rosuvastatin Calcium	196	$2,153
Atorvastatin Calcium	91	$1,408
Ezetimibe	56	$804
Diltiazem 24hr Er (Cd)Diltiazem Hcl	36	$725
Nitroglycerin	39	$566
Carvedilol	84	$551
Flecainide Acetate	12	$509
Amiodarone Hcl	17	$413
Atenolol	11	$379
ClopidogrelClopidogrel Bisulfate	22	$349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$468	$104,58496 claims
Johnson & JohnsonXarelto	$57	$16,69513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,250 cardiovascular disease providers in Pennsylvania.